miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma

M Díaz-Martínez, L Benito-Jardón, L Alonso… - Cancer research, 2018 - AACR
Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic
benefits but the common emergence of drug resistance remains a challenge. We generated …
被引用次数：151 相关文章

miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma

M Díaz-Martínez, L Benito-Jardón, L Alonso… - Cancer …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Melanoma treatment with the BRAF V600E
inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug …
[HTML] nih.gov

[HTML][HTML] miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma

M Díaz-Martínez, L Benito-Jardón, L Alonso… - Cancer …, 2018 - ncbi.nlm.nih.gov
Melanoma treatment with the BRAF V600E inhibitor vemurafenib (VMF) provides therapeutic
benefits but the common emergence of drug resistance remains a challenge. We generated …

miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma

M Díaz-Martínez, L Benito-Jardón, L Alonso… - 2018 - digital.csic.es
Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic
benefits but the common emergence of drug resistance remains a challenge. We generated …

miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma

M Díaz-Martínez, L Benito-Jardón… - Cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Melanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic
benefits but the common emergence of drug resistance remains a challenge. We generated …

miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.

M Díaz-Martínez, L Benito-Jardón, L Alonso… - Cancer …, 2017 - europepmc.org
Melanoma treatment with the BRAF V600E inhibitor vemurafenib (VMF) provides therapeutic
benefits but the common emergence of drug resistance remains a challenge. We generated …